TRIAL RESULTS · SIDE EFFECTS
Goserelin side effects
ANSWER
In 2 placebo-controlled trials with posted results, the most common side effects of Goserelin were neutropenia 57.9% (placebo 6.5%), arthralgia 38.8% (placebo 36.2%), neutrophil count decreased 35.5% (placebo 1.5%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
15
with an arm on Goserelin, of 449 registered
Against placebo
2
placebo-controlled trials
People in those trials
494
on Goserelin · 461 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Goserelin beside placebo
Share of people with each side effect in 2 placebo-controlled trials with posted results: 494 people on Goserelin (all doses), 461 on placebo, same trials. Listed only when reported for at least half of the people on Goserelin. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
The 100 most reported of 658 side effects reported
Every trial with posted results and an arm on Goserelin (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Goserelin | Placebo | Trials |
|---|---|---|---|---|
| Hot flashes | Endocrine disorders | 90.7% (902 of 994) | - | 3 |
| Fatigue/malaise/lethargy | General disorders | 68.1% (633 of 929) | - | 1 |
| Leukopenia | Investigations | 31.5% (408 of 1,295) | 3.9% | 3 |
| Erectile impotence | Reproductive system and breast disorders | 35.8% (389 of 1,088) | 0.0% | 2 |
| Nausea | Gastrointestinal disorders | 22.1% (387 of 1,752) | 19.1% | 9 |
| Hot flush | Vascular disorders | 31.6% (346 of 1,095) | 34.7% | 6 |
| Weight gain | Investigations | 30.3% (341 of 1,127) | 2.4% | 3 |
| Pain-other | General disorders | 36.1% (335 of 929) | - | 1 |
| Libido loss | Reproductive system and breast disorders | 32.5% (302 of 929) | - | 1 |
| Alopecia | Skin and subcutaneous tissue disorders | 20.3% (301 of 1,481) | 9.1% | 5 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 20.1% (293 of 1,459) | 36.2% | 6 |
| Insomnia | Psychiatric disorders | 17.7% (274 of 1,551) | 14.3% | 7 |
| Sweating | General disorders | 29.3% (272 of 929) | - | 1 |
| Headache | Nervous system disorders | 15.2% (266 of 1,747) | 22.1% | 9 |
| Urinary frequency/urgency | Renal and urinary disorders | 24.1% (262 of 1,088) | 3.2% | 2 |
| Incontinence | Renal and urinary disorders | 23.3% (254 of 1,088) | 1.6% | 2 |
| Neutropenia/granulocytopenia | Investigations | 27.2% (253 of 929) | - | 1 |
| Gynecomastia | Endocrine disorders | 21.7% (244 of 1,127) | 3.2% | 3 |
| Anemia | Blood and lymphatic system disorders | 25.4% (243 of 955) | - | 2 |
| Hypertension | Cardiac disorders | 10.4% (223 of 2,152) | 6.7% | 8 |
| Depression | Psychiatric disorders | 16.7% (217 of 1,303) | 6.8% | 3 |
| Constipation/bowel obstruction | Gastrointestinal disorders | 21.7% (202 of 929) | - | 1 |
| Neutropenia | Blood and lymphatic system disorders | 57.9% (194 of 335) | 6.5% | 1 |
| Fatigue | General disorders | 16.0% (186 of 1,160) | 25.5% | 8 |
| Hyperglycemia | Metabolism and nutrition disorders | 15.3% (166 of 1,088) | 19.4% | 2 |
| Cough | Respiratory, thoracic and mediastinal disorders | 9.8% (162 of 1,649) | 10.8% | 8 |
| Vomiting | Gastrointestinal disorders | 9.6% (155 of 1,618) | 13.9% | 7 |
| Diarrhea without colostomy | Gastrointestinal disorders | 16.0% (149 of 929) | - | 1 |
| Neutrophil count decreased | Investigations | 39.3% (142 of 361) | 1.5% | 2 |
| Muscle weakness (not neuro) | Musculoskeletal and connective tissue disorders | 15.2% (141 of 929) | - | 1 |
| Myalgia | Musculoskeletal and connective tissue disorders | 9.5% (139 of 1,464) | 12.5% | 6 |
| Rash/desquamation | Skin and subcutaneous tissue disorders | 12.2% (133 of 1,088) | 11.3% | 2 |
| Sensory neuropathy | Nervous system disorders | 14.1% (131 of 929) | - | 1 |
| Anxiety/agitation | Psychiatric disorders | 13.9% (129 of 929) | - | 1 |
| Back pain | Musculoskeletal and connective tissue disorders | 11.9% (127 of 1,064) | 21.4% | 6 |
| Dizziness/light headedness | Nervous system disorders | 12.9% (120 of 929) | - | 1 |
| Edema | Cardiac disorders | 10.4% (117 of 1,120) | 8.9% | 3 |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | 9.9% (102 of 1,026) | - | 4 |
| SGOT (AST) increase | Investigations | 10.1% (94 of 929) | - | 1 |
| Bone pain | Musculoskeletal and connective tissue disorders | 6.4% (93 of 1,449) | 7.2% | 4 |
| Lymphopenia | Investigations | 6.2% (90 of 1,454) | 2.0% | 4 |
| Pruritus | Skin and subcutaneous tissue disorders | 6.0% (88 of 1,462) | 4.6% | 4 |
| Anaemia | Blood and lymphatic system disorders | 7.6% (86 of 1,128) | 11.0% | 6 |
| Dry skin | Skin and subcutaneous tissue disorders | 5.6% (85 of 1,520) | 2.8% | 6 |
| Diarrhoea | Gastrointestinal disorders | 23.0% (84 of 366) | 19.9% | 2 |
| Abdominal pain/cramping | Gastrointestinal disorders | 8.9% (83 of 929) | - | 1 |
| Pyrexia | General disorders | 8.0% (80 of 999) | 8.6% | 4 |
| Urinary tract infection | Infections and infestations | 7.3% (78 of 1,064) | 9.2% | 6 |
| Constipation | Gastrointestinal disorders | 11.9% (74 of 622) | 17.4% | 6 |
| Rash | Skin and subcutaneous tissue disorders | 13.2% (69 of 522) | 9.5% | 5 |
| Thrombocytopenia | Investigations | 5.3% (67 of 1,264) | 1.8% | 2 |
| Alanine aminotransferase increased | Investigations | 14.2% (66 of 464) | 10.1% | 4 |
| Asthenia | General disorders | 7.4% (65 of 878) | 12.8% | 5 |
| Arthritis | Musculoskeletal and connective tissue disorders | 5.7% (63 of 1,114) | 0.8% | 3 |
| Nail changes | Skin and subcutaneous tissue disorders | 5.8% (63 of 1,088) | 1.6% | 2 |
| Aspartate aminotransferase increased | Investigations | 13.4% (62 of 464) | 10.7% | 4 |
| Hot flashes/flushes | Vascular disorders | 60.2% (62 of 103) | - | 1 |
| Weight increased | Investigations | 5.9% (59 of 999) | 3.0% | 4 |
| SGPT (ALT) increase | Investigations | 6.1% (57 of 929) | - | 1 |
| Stomatitis/pharyngitis | Gastrointestinal disorders | 6.0% (56 of 929) | - | 1 |
| Anorexia | Metabolism and nutrition disorders | 4.8% (55 of 1,153) | 1.6% | 4 |
| Dyspepsia/heartburn | Gastrointestinal disorders | 5.1% (55 of 1,088) | 4.0% | 2 |
| White blood cell count decreased | Investigations | 16.4% (55 of 335) | 1.2% | 1 |
| Weight loss | Investigations | 4.7% (54 of 1,159) | 0.8% | 4 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 14.4% (54 of 374) | 13.1% | 2 |
| Upper respiratory tract infection | Infections and infestations | 15.8% (53 of 335) | 11.9% | 1 |
| Joint,muscle,bone-other | Musculoskeletal and connective tissue disorders | 5.5% (51 of 929) | - | 1 |
| Nasopharyngitis | Infections and infestations | 11.5% (50 of 433) | 6.8% | 2 |
| Stomatitis | Gastrointestinal disorders | 13.7% (50 of 366) | 8.9% | 2 |
| Urine color change | Renal and urinary disorders | 5.2% (48 of 929) | - | 1 |
| Taste disturbance | Gastrointestinal disorders | 5.1% (47 of 929) | - | 1 |
| Hot Flush | Vascular disorders | 33.3% (43 of 129) | - | 2 |
| GI-other | Gastrointestinal disorders | 4.5% (42 of 929) | - | 1 |
| Electrocardiogram QT prolonged | Investigations | 12.5% (42 of 335) | 4.7% | 1 |
| Dizziness | Nervous system disorders | 8.9% (41 of 463) | 7.4% | 5 |
| Oedema peripheral | General disorders | 4.6% (41 of 901) | 5.3% | 3 |
| Chest pain,not cardio or pleur | General disorders | 4.2% (39 of 929) | - | 1 |
| Abdominal pain | Gastrointestinal disorders | 11.6% (39 of 335) | 8.0% | 1 |
| HOT FLUSH | Vascular disorders | 16.7% (37 of 221) | - | 1 |
| Vaginal dryness | Reproductive system and breast disorders | 26.7% (36 of 135) | - | 2 |
| Pain - Head/headache | Nervous system disorders | 35.0% (36 of 103) | - | 1 |
| Sweating (diaphoresis) | Skin and subcutaneous tissue disorders | 13.4% (35 of 262) | 0.0% | 2 |
| Creatinine increase | Investigations | 3.7% (34 of 929) | - | 1 |
| Decreased appetite | Metabolism and nutrition disorders | 10.1% (34 of 335) | 8.0% | 1 |
| Rigors/chills | General disorders | 3.0% (33 of 1,088) | 1.6% | 2 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 9.9% (33 of 335) | 5.3% | 1 |
| Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | 3.2% (31 of 968) | - | 2 |
| Mood alteration - anxiety | Psychiatric disorders | 30.1% (31 of 103) | - | 1 |
| Influenza | Infections and infestations | 8.7% (29 of 335) | 7.1% | 1 |
| Non-cardiac chest pain | General disorders | 3.0% (28 of 940) | 4.5% | 4 |
| Mood alteration - depression | Psychiatric disorders | 27.2% (28 of 103) | - | 1 |
| Dyspepsia | Gastrointestinal disorders | 2.8% (27 of 966) | 4.2% | 5 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 6.2% (27 of 433) | 6.2% | 2 |
| Abdominal pain upper | Gastrointestinal disorders | 8.1% (27 of 335) | 7.1% | 1 |
| Breast pain | Reproductive system and breast disorders | 6.5% (26 of 400) | 6.8% | 3 |
| White blood cell decreased | Investigations | 100.0% (26 of 26) | - | 1 |
| Anxiety | Psychiatric disorders | 6.3% (25 of 400) | 5.0% | 3 |
| Amenorrhoea | Reproductive system and breast disorders | 24.5% (24 of 98) | - | 1 |
| Erectile dysfunction | Reproductive system and breast disorders | 11.4% (23 of 201) | - | 3 |
| Libido | Psychiatric disorders | 8.8% (23 of 262) | 0.0% | 2 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
QUESTIONS
Does goserelin cause neutropenia?
In 2 placebo-controlled trials with posted results, 57.9% of people on goserelin reported neutropenia, against 6.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does goserelin cause arthralgia?
In 2 placebo-controlled trials with posted results, 38.8% of people on goserelin reported arthralgia, against 36.2% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does goserelin cause neutrophil count decreased?
In 2 placebo-controlled trials with posted results, 35.5% of people on goserelin reported neutrophil count decreased, against 1.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does goserelin cause hot flush?
In 2 placebo-controlled trials with posted results, 35.2% of people on goserelin reported hot flush, against 34.7% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does goserelin cause fatigue?
In 2 placebo-controlled trials with posted results, 26.6% of people on goserelin reported fatigue, against 25.5% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
449 registered clinical trials of Goserelin
The 10 most recently updated are listed.
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer Status: RECRUITING · Updated 2026-10-02 |
|---|---|
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Status: ACTIVE_NOT_RECRUITING · Updated 2026-10-01 |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib Status: ACTIVE_NOT_RECRUITING · Updated 2026-10-01 |
| NCT07460752 | Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients Status: RECRUITING · Updated 2026-10-01 |
| 2022-501024-20-00 | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence Status: UNKNOWN · Updated 2026-09-29 |
| 2026-525328-10-00 | A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA) Status: UNKNOWN · Updated 2026-09-28 |
| NCT01723774 | PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-25 |
| NCT07287098 | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer Status: RECRUITING · Updated 2026-09-22 |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-17 |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) Status: RECRUITING · Updated 2026-09-17 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.